Well, based on the BUB case, 'priced in' would be a 40% increase in SP. I think that in itself is way more than what the specifics of the deal justify, but I'm not Mr Market, I'm just Mr Me.
However, relative to that, a 10% increase seems on par given that A2's FDA application is also confirmed as being under review. I was sceptical whether theyd actually move on that, but I'm less sceptical that it'll be granted by the FDA.
A2 Managment has Baby Nap... while Bubs Australia ships 27.5 Million Formula Bottles to U.S, page-125
-
- There are more pages in this discussion • 104 more messages in this thread...
You’re viewing a single post only. To view the entire thread just sign in or Join Now (FREE)
Add A2M (ASX) to my watchlist
 (20min delay)
|
|||||
|
Last
$5.56 |
Change
0.030(0.54%) |
Mkt cap ! $4.025B | |||
| Open | High | Low | Value | Volume |
| $5.50 | $5.61 | $5.49 | $7.155M | 1.289M |
Buyers (Bids)
| No. | Vol. | Price($) |
|---|---|---|
| 2 | 6277 | $5.54 |
Sellers (Offers)
| Price($) | Vol. | No. |
|---|---|---|
| $5.57 | 11611 | 5 |
View Market Depth
| Last trade - 16.10pm 06/09/2024 (20 minute delay) ? |
| A2M (ASX) Chart |